ReviewCancer immunology, immunotherapy : CII2016
Concepts in glioma immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Differentiation of Intracerebral Tumor Entities with Quantitative Contrast Attenuation and Iodine Mapping in Dual-Layer Computed Tomography.Diagnostics (Basel, Switzerland) · 2022Article
- RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.Scientific reports · 2022Article
- Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomas.Frontiers in immunology · 2022Article
- Identification and validation of RNA-binding protein-related gene signature revealed potential associations with immunosuppression and drug sensitivity in glioma.Cancer medicine · 2021Article
- Driving mesenchymal transition in glioblastoma.Neuro-oncology · 2020Article
- High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas.Frontiers in oncology · 2020Article
- Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.Expert review of neurotherapeutics · 2019Review
- Tumor growth under rhGM-CSF application in an orthotopic rodent glioma model.Oncology letters · 2019Article
- Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.World neurosurgery · 2019Review
- Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.CNS neuroscience & therapeutics · 2019Article
- Article
- Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells.Journal of extracellular vesicles · 2019Article
- Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.Neuro-oncology · 2018Article
- Mesenchymal Stromal Stem Cell-Derived Microvesicles Enhance Tumor Lysate Pulsed Dendritic Cell Stimulated Autologous T lymphocyte CytotoxicityAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Vaccine Strategies in Gliomas.Current treatment options in neurology · 2018Review
- Glioblastoma Treatments: An Account of Recent Industrial Developments.Frontiers in pharmacology · 2018Review
- NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma.Cell communication and signaling : CCS · 2017Article
- Management of GBM: a problem of local recurrence.Journal of neuro-oncology · 2017Review
- Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.Journal of neuro-oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapeutic concepts in neurooncology have been developed for many decades but have mainly been hampered by poor definition of relevant antigens and selective measures to target the central nervous system. Independent of the recent remarkable successes in clinical immunooncology with checkpoint inhibitors and vaccines, immunotherapy of brain tumors in general and gliomas in particular has evolved with novel neurooncology-specific concepts over the past years providing new phase 1 approaches of individualized immunotherapy to first phase three clinical trials. These concepts are driven by a high medical need in the absence of approved targeted therapies and refute the classic dogma that the central nervous system is immune-privileged and hence inaccessible to potent antitumor immunity. Instead, measures have been taken to improve the odds for successful immunotherapies, including rational targeting of relevant antigens and integration of immunotherapies into standard of care primary radiochemotherapy to increase the efficacy of antitumor immunity in a meaningful time window. This review highlights concepts and challenges associated with epitope discovery and selection and trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.